BPG is committed to discovery and dissemination of knowledge
Articles in Press
3/6/2026 7:29:10 AM | Browse: 9 | Download: 0
| Category |
Oncology |
| Manuscript Type |
Randomized Controlled Trial |
| Article Title |
Investigation of interaction between sodium-glucose cotransporter 2 inhibitors and FOLFOX with colorectal cancer and type 2 diabetes
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Bin Liu, Ning Su, Qing-Shi Lin, Yan-Qin Huang and Shao-Feng Chen |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Shao-Feng Chen, Associate Chief Pharmacist, Department of Pharmacy, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, No. 201 Hubin South Road, Xiamen 361004, Fujian Province, China. csfcby@163.com |
| Key Words |
Sodium-glucose cotransporter 2 inhibitors; Colorectal cancer; mFOLFOX6; Type 2 diabetes mellitus; Survival rate; Dapagliflozin |
| Core Tip |
In this study, we evaluated the addition of the sodium-glucose cotransporter 2 inhibitor dapagliflozin to standard mFOLFOX6 chemotherapy in patients with stage III colorectal cancer and type 2 diabetes mellitus after curative resection. The combination significantly improved glycemic control, reduced carcinoembryonic antigen levels, and enhanced 3-year disease-free survival without increasing severe chemotherapy-related toxicity. These findings suggest that sodium-glucose cotransporter 2 inhibitor may offer dual metabolic and oncological benefits in this high-risk comorbid population, supporting its repurposing as an adjunct to adjuvant chemotherapy. |
| Citation |
Liu B, Su N, Lin QS, Huang YQ, Chen SF. Investigation of interaction between sodium-glucose cotransporter 2 inhibitors and FOLFOX with colorectal cancer and type 2 diabetes. World J Gastrointest Oncol 2026; In press |
 |
Received |
|
2026-01-16 09:40 |
 |
Peer-Review Started |
|
2026-01-16 09:40 |
 |
First Decision by Editorial Office Director |
|
2026-01-27 07:27 |
 |
Return for Revision |
|
2026-01-27 07:27 |
 |
Revised |
|
2026-02-02 07:41 |
 |
Publication Fee Transferred |
|
2026-02-05 09:07 |
 |
Second Decision by Editor |
|
2026-03-06 02:36 |
 |
Second Decision by Editor-in-Chief |
|
|
 |
Final Decision by Editorial Office Director |
|
2026-03-06 07:29 |
 |
Articles in Press |
|
2026-03-06 07:29 |
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
|
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
© 1993-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345